TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Icecure Medical ( (ICCM) ) just unveiled an announcement.
IceCure Medical Ltd. has announced a Special General Meeting of Shareholders scheduled for January 7, 2026, where shareholders will vote on key proposals including updates to the compensation of the CEO and Chairman, and amendments to the company’s Articles of Association. The meeting is significant for stakeholders as it involves decisions that could impact the company’s governance and executive compensation structure.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. The technical analysis indicates a bearish trend, and valuation metrics are weak due to unprofitability. However, the positive sentiment from the earnings call, driven by FDA approval and strategic market opportunities, provides some optimism for future growth.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. operates in the medical technology industry and is known for developing minimally invasive cryoablation therapies for the treatment of tumors. The company focuses on providing innovative solutions for the healthcare market, particularly in the area of cancer treatment.
Average Trading Volume: 1,235,103
Technical Sentiment Signal: Sell
Current Market Cap: $49.12M
Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.